CATALYST PHARMACEUTICALS INC Share Price Today: Live Updates & Key Insights

CATALYST PHARMACEUTICALS INC share price today is $22.75, up 2.06%. The stock opened at $22.21 against the previous close of $22.33, with an intraday high of $22.85 and low of $22.21.

CATALYST PHARMACEUTICALS INC Share Price Chart

CATALYST PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
us-stock

CATALYST PHARMACEUTICALS INC Share Price Performance

$22.75 0.0206(2.06%) CPRX at 23 Mar 2026 12:33 PM Biotechnology
Lowest Today 22.21
Highest Today 22.85
Today’s Open 22.21
Prev. Close 22.33
52 Week High 26.58
52 Week Low 19.05
Day’s Range: Low 22.21 High 22.85
52-Week Range: Low 19.05 High 26.58
1 day return -
1 Week return -2.18
1 month return -5.47
3 month return -6.29
6 month return +13.7
1 year return -11.49
3 year return +40.61
5 year return +386.23
10 year return -

CATALYST PHARMACEUTICALS INC Institutional Holdings

BlackRock Inc 14.92

Vanguard Group Inc 6.90

iShares Core S&P Small-Cap ETF 5.73

State Street Corp 5.25

Deerfield Management Co 4.02

Vanguard Total Stock Mkt Idx Inv 3.01

Fundsmith LLP 2.75

Smithson Investment Trust Ord 2.75

Avantis US Small Cap Value ETF 2.60

American Century Companies Inc 2.48

Dimensional Fund Advisors, Inc. 2.45

Geode Capital Management, LLC 2.37

iShares Russell 2000 ETF 2.29

Renaissance Technologies Corp 2.17

State Street® SPDR® S&P® Biotech ETF 2.13

Bank of America Corp 1.88

Royce & Associates, LP 1.56

Morgan Stanley - Brokerage Accounts 1.51

Arrowstreet Capital Limited Partnership 1.32

Charles Schwab Investment Management Inc 1.11

Northern Trust Corp 1.03

Vanguard Institutional Extnd Mkt Idx Tr 1.02

Amvescap Plc. 1.01

Boston Partners Global Investors, Inc 1.01

Kennedy Capital Management Inc 0.99

Fidelity Small Cap Index 0.93

State Street SPDR Port S&P 600 Sm CpETF 0.88

The Goldman Sachs Group Inc 0.82

Millennium Management LLC 0.81

iShares S&P Small-Cap 600 Growth ETF 0.81

iShares Russell 2000 Growth ETF 0.79

Janus Henderson Hrzn Glb SC E2 USD 0.79

Kennedy Small Cap Value 0.70

Vanguard Tax-Managed Small Cap Adm 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.55

State Street® SPDR® S&P 600™ Sm Cp GrETF 0.49

Fidelity Extended Market Index 0.49

Schwab US Small-Cap ETF™ 0.46

Oberweis Micro-Cap 0.46

Oberweis Micro-Cap Growth 0.46

CATALYST PHARMACEUTICALS INC Market Status

Strong Buy: 6

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

CATALYST PHARMACEUTICALS INC Fundamentals

Market Cap 2801.17 M

PB Ratio 2.9166

PE Ratio 13.3275

Enterprise Value 2076.82 M

Total Assets 1106.81 M

Volume 3188853

CATALYST PHARMACEUTICALS INC Company Financials

Annual Revenue FY25:588989000 589.0M, FY23:348393000 348.4M, FY22:214203000 214.2M, FY21:140833000 140.8M, FY20:119072803 119.1M

Annual Profit FY25:501736000 501.7M, FY23:301040000 301.0M, FY22:179810000 179.8M, FY21:118949000 118.9M, FY20:102033646 102.0M

Annual Net worth FY25:214326000 214.3M, FY23:62037000 62.0M, FY22:83079000 83.1M, FY21:39482000 39.5M, FY20:74983000 75.0M

Quarterly Revenue Q4/2025:152613000 152.6M, Q3/2025:148392000 148.4M, Q2/2025:146563000 146.6M, Q1/2025:141421000 141.4M, Q3/2024:128695000 128.7M

Quarterly Profit Q4/2025:138540000 138.5M, Q3/2025:123081000 123.1M, Q2/2025:116605000 116.6M, Q1/2025:123510000 123.5M, Q3/2024:109418000 109.4M

Quarterly Net worth Q4/2025:52698000 52.7M, Q3/2025:52783000 52.8M, Q2/2025:52108000 52.1M, Q1/2025:56737000 56.7M, Q3/2024:43884000 43.9M

About CATALYST PHARMACEUTICALS INC & investment objective

Company Information Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Organisation Biotechnology

Employees 182

Industry Biotechnology

CEO Mr. Richard John Daly M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

CATALYST PHARMACEUTICALS INC FAQs

What is the share price of CATALYST PHARMACEUTICALS INC today?

The current share price of CATALYST PHARMACEUTICALS INC is $22.75.

Can I buy CATALYST PHARMACEUTICALS INC shares in India?

Yes, Indian investors can buy CATALYST PHARMACEUTICALS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy CATALYST PHARMACEUTICALS INC shares in India?

You can easily invest in CATALYST PHARMACEUTICALS INC shares from India by:

Can I buy fractional shares of CATALYST PHARMACEUTICALS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC has a market cap of $2801.17 M.

In which sector does CATALYST PHARMACEUTICALS INC belong?

CATALYST PHARMACEUTICALS INC operates in the Biotechnology sector.

What documents are required to invest in CATALYST PHARMACEUTICALS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of CATALYST PHARMACEUTICALS INC?

The PE ratio of CATALYST PHARMACEUTICALS INC is 13.33 and the PB ratio is 2.92.